APPLY

2026

Winner of the €100,000 Jorge Ruas Award

SafeAlleleSCA: Allele-Specific AAV Gene Therapy for Dominant Spinocerebellar Ataxias

SafeAlleleSCA is a first-in-class gene therapy platform designed to selectively silence the disease-causing genetic variant while preserving normal gene function.

Its lead programme targets Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph disease, a rare, inherited and progressive neurodegenerative disorder that leads to a gradual loss of coordination, balance and muscle control.

Preclinical studies have shown strong efficacy in mouse models and broad distribution of the therapy across relevant areas of the central nervous system in non-human primates.

Team:
Ana Carolina Silva
Diogo Magalhães e Silva
Laetitia Gaspar
Luís Pereira de Almeida
Rui Jorge Nobre

Organisation:
GeneT (Gene Therapy Center of Excellence) – University of Coimbra